{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:16:18Z","timestamp":1787505378208,"version":"build-2736575974"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"DOI":"10.1007\/s00011-025-02166-6","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:45:47Z","timestamp":1767879947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide"],"prefix":"10.1007","volume":"75","author":[{"given":"Vito","family":"Evola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"3","key":"2166_CR1","volume":"17","author":"D Shreya","year":"2025","unstructured":"Shreya D, Fish PN, Du D. Navigating the future of elderly healthcare: a comprehensive analysis of aging populations and mortality trends using National Inpatient Sample (NIS) data (2010\u20132024). Cureus. 2025;17(3):e80442.","journal-title":"Cureus"},{"issue":"5","key":"2166_CR2","first-page":"2937","volume":"16","author":"S Wang","year":"2024","unstructured":"Wang S, et al. The expanding burden of neurodegenerative diseases: an unmet medical and social need. Aging Dis. 2024;16(5):2937\u201352.","journal-title":"Aging Dis"},{"key":"2166_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59061084","author":"AB Reiss","year":"2023","unstructured":"Reiss AB, et al. Alzheimer\u2019s disease treatment: the search for a breakthrough. Medicina (Kaunas). 2023. https:\/\/doi.org\/10.3390\/medicina59061084.","journal-title":"Medicina (Kaunas)"},{"key":"2166_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells13181527","author":"A Mahboob","year":"2024","unstructured":"Mahboob A, et al. Immunotherapy for Parkinson\u2019s disease and Alzheimer\u2019s disease: a promising disease-modifying therapy. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13181527.","journal-title":"Cells"},{"key":"2166_CR5","doi-asserted-by":"publisher","unstructured":"Angelica O et al. From lab bench to hope: emerging gene therapies in clinical trials for Alzheimer\u2019s disease. 2024. https:\/\/doi.org\/10.1007\/s12035-024-04285-3.","DOI":"10.1007\/s12035-024-04285-3"},{"key":"2166_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07599-1","author":"J Grote","year":"2024","unstructured":"Grote J, et al. From lab bench to hope: a review of gene therapies in clinical trials for Parkinson\u2019s disease and challenges. Neurol Sci. 2024. https:\/\/doi.org\/10.1007\/s10072-024-07599-1.","journal-title":"Neurol Sci"},{"key":"2166_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123001","volume":"355","author":"J Tran","year":"2024","unstructured":"Tran J, et al. Repurposing antidiabetic drugs for Alzheimer\u2019s disease: a review of preclinical and clinical evidence and overcoming challenges. Life Sci. 2024;355:123001.","journal-title":"Life Sci"},{"key":"2166_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073995","author":"PM Giri","year":"2024","unstructured":"Giri PM, et al. Neuroinflammation in neurodegenerative disorders: current knowledge and therapeutic implications. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25073995.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2166_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9(1):42.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"2166_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, et al. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8(1):267.","journal-title":"Signal Transduct Target Ther"},{"key":"2166_CR11","doi-asserted-by":"publisher","first-page":"1347987","DOI":"10.3389\/fnagi.2024.1347987","volume":"16","author":"A Adamu","year":"2024","unstructured":"Adamu A, et al. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front Aging Neurosci. 2024;16:1347987.","journal-title":"Front Aging Neurosci"},{"key":"2166_CR12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","author":"S Gabery","year":"2020","unstructured":"Gabery S, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.133429.","journal-title":"JCI Insight"},{"key":"2166_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2025.100518","volume":"52","author":"C Odigwe","year":"2025","unstructured":"Odigwe C, et al. Emerging role of GLP-1 agonists in cardio-metabolic therapy - focus on Semaglutide. Am Heart J Plus Cardiol Res Pr. 2025;52:100518.","journal-title":"Am Heart J Plus Cardiol Res Pr"},{"key":"2166_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.","journal-title":"BMJ"},{"issue":"11","key":"2166_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"2166_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","volume":"1","author":"Y Seino","year":"2010","unstructured":"Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1(1\u20132):8\u201323.","journal-title":"J Diabetes Investig"},{"key":"2166_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221857","author":"SO Lee","year":"2024","unstructured":"Lee SO, et al. Semaglutide ameliorates diabetic neuropathic pain by inhibiting neuroinflammation in the spinal cord. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13221857.","journal-title":"Cells"},{"key":"2166_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117531","volume":"250","author":"Q Li","year":"2020","unstructured":"Li Q, et al. Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats. Life Sci. 2020;250:117531.","journal-title":"Life Sci"},{"key":"2166_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9080926","author":"R Sim\u00f3","year":"2021","unstructured":"Sim\u00f3 R, et al. Effects of the topical administration of semaglutide on retinal neuroinflammation and vascular leakage in experimental diabetes. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9080926.","journal-title":"Biomedicines"},{"key":"2166_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.neuroscience.2024.11.022","volume":"563","author":"ZJ Wang","year":"2024","unstructured":"Wang ZJ, et al. Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP\/PS1\/tau mice. Neuroscience. 2024;563:222\u201334.","journal-title":"Neuroscience"},{"key":"2166_CR21","doi-asserted-by":"publisher","first-page":"1398059","DOI":"10.3389\/fnut.2024.1398059","volume":"11","author":"R Tamayo-Trujillo","year":"2024","unstructured":"Tamayo-Trujillo R, et al. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. Front Nutr. 2024;11:1398059.","journal-title":"Front Nutr"},{"issue":"12","key":"2166_CR22","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.3390\/cimb46120872","volume":"46","author":"I Papakonstantinou","year":"2024","unstructured":"Papakonstantinou I, Tsioufis K, Katsi V. Spotlight on the mechanism of action of Semaglutide. Curr Issues Mol Biol. 2024;46(12):14514\u201341.","journal-title":"Curr Issues Mol Biol"},{"issue":"31","key":"2166_CR23","doi-asserted-by":"publisher","first-page":"12728","DOI":"10.1073\/pnas.1118748109","volume":"109","author":"J Lampa","year":"2012","unstructured":"Lampa J, et al. Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice. Proc Natl Acad Sci U S A. 2012;109(31):12728\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2166_CR24","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/s41423-021-00757-x","volume":"18","author":"I Galea","year":"2021","unstructured":"Galea I. The blood-brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021;18(11):2489\u2013501.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2166_CR25","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.1038\/s41467-019-13812-z","volume":"10","author":"K Haruwaka","year":"2019","unstructured":"Haruwaka K, et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun. 2019;10(1):5816.","journal-title":"Nat Commun"},{"issue":"3","key":"2166_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151702","volume":"11","author":"LD Jones","year":"2016","unstructured":"Jones LD, Jackson JW, Maggirwar SB. Modeling HIV-1 induced neuroinflammation in mice: role of platelets in mediating blood-brain barrier dysfunction. PLoS ONE. 2016;11(3):e0151702.","journal-title":"PLoS ONE"},{"issue":"4","key":"2166_CR27","doi-asserted-by":"publisher","first-page":"368504211054985","DOI":"10.1177\/00368504211054985","volume":"104","author":"T Ishijima","year":"2021","unstructured":"Ishijima T, Nakajima K. Inflammatory cytokines TNF\u03b1, IL-1\u03b2, and IL-6 are induced in endotoxin- stimulated microglia through different signaling cascades. Sci Prog. 2021;104(4):368504211054985.","journal-title":"Sci Prog"},{"issue":"7638","key":"2166_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481\u20137.","journal-title":"Nature"},{"key":"2166_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.825086","volume":"14","author":"F Shao","year":"2022","unstructured":"Shao F, et al. Microglia and neuroinflammation: crucial pathological mechanisms in traumatic brain injury-induced neurodegeneration. Front Aging Neurosci. 2022;14:825086.","journal-title":"Front Aging Neurosci"},{"issue":"8017","key":"2166_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41586-024-07469-y","volume":"630","author":"H Jin","year":"2024","unstructured":"Jin H, et al. A body-brain circuit that regulates body inflammatory responses. Nature. 2024;630(8017):695\u2013703.","journal-title":"Nature"},{"issue":"9","key":"2166_CR31","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2018-02685","volume":"104","author":"VA Fonseca","year":"2019","unstructured":"Fonseca VA, et al. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. J Clin Endocrinol Metab. 2019;104(9):4078\u201386.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2166_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","volume":"21","author":"O Mosenzon","year":"2022","unstructured":"Mosenzon O, et al. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol. 2022;21(1):172.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2166_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0326897","volume":"20","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, et al. Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes. PLoS ONE. 2025;20(7):e0326897.","journal-title":"PLoS ONE"},{"key":"2166_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109647","volume":"115","author":"MA Sadek","year":"2023","unstructured":"Sadek MA, et al. Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway. Int Immunopharmacol. 2023;115:109647.","journal-title":"Int Immunopharmacol"},{"key":"2166_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.970925","volume":"16","author":"N Reich","year":"2022","unstructured":"Reich N, H\u00f6lscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review. Front Neurosci. 2022;16:970925.","journal-title":"Front Neurosci"},{"issue":"2","key":"2166_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","volume":"16","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Wang X. Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell. 2025;16(2):83\u2013120.","journal-title":"Protein Cell"},{"key":"2166_CR37","first-page":"575","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, et al. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement. 2018;4:575\u201390.","journal-title":"Alzheimers Dement"},{"key":"2166_CR38","doi-asserted-by":"publisher","first-page":"1201982","DOI":"10.3389\/fnagi.2023.1201982","volume":"15","author":"J Miao","year":"2023","unstructured":"Miao J, et al. Microglia in Alzheimer\u2019s disease: pathogenesis, mechanisms, and therapeutic potentials. Front Aging Neurosci. 2023;15:1201982.","journal-title":"Front Aging Neurosci"},{"key":"2166_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.815347","volume":"14","author":"S Guo","year":"2022","unstructured":"Guo S, Wang H, Yin Y. Microglia polarization from M1 to M2 in neurodegenerative diseases. Front Aging Neurosci. 2022;14:815347.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"2166_CR40","first-page":"1537","volume":"15","author":"Q Deng","year":"2024","unstructured":"Deng Q, et al. Microglia and astrocytes in Alzheimer\u2019s disease: significance and summary of recent advances. Aging Dis. 2024;15(4):1537\u201364.","journal-title":"Aging Dis"},{"key":"2166_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062440","author":"AI Beltran-Velasco","year":"2025","unstructured":"Beltran-Velasco AI, Clemente-Su\u00e1rez VJ. Impact of peripheral inflammation on blood-brain barrier dysfunction and its role in neurodegenerative diseases. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26062440.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2166_CR42","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/13872877251329439","volume":"105","author":"Y Zhai","year":"2025","unstructured":"Zhai Y, et al. Semaglutide improves cognitive function and neuroinflammation in APP\/PS1 transgenic mice by activating AMPK and inhibiting TLR4\/NF-\u03baB pathway. J Alzheimers Dis. 2025;105(2):416\u201332.","journal-title":"J Alzheimers Dis"},{"key":"2166_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117540","volume":"180","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Semaglutide ameliorates Alzheimer\u2019s disease and restores oxytocin in APP\/PS1 mice and human brain organoid models. Biomed Pharmacother. 2024;180:117540.","journal-title":"Biomed Pharmacother"},{"key":"2166_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102019","volume":"89","author":"L Forny Germano","year":"2024","unstructured":"Forny Germano L, et al. The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice. Mol Metab. 2024;89:102019.","journal-title":"Mol Metab"},{"key":"2166_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177305","volume":"991","author":"NN Elbadawy","year":"2025","unstructured":"Elbadawy NN, et al. The GLP-1 agonist semaglutide ameliorates cognitive regression in P301S tauopathy mice model via autophagy\/ACE2\/SIRT1\/FOXO1-mediated microglia polarization. Eur J Pharmacol. 2025;991:177305.","journal-title":"Eur J Pharmacol"},{"key":"2166_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109716","volume":"240","author":"ZJ Wang","year":"2023","unstructured":"Wang ZJ, et al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway. Neuropharmacology. 2023;240:109716.","journal-title":"Neuropharmacology"},{"key":"2166_CR47","doi-asserted-by":"crossref","unstructured":"Ludwig M et al. A lipopolysaccharide mouse model mirrors neuroinflammatory transcriptional signatures of human AD, and the glucagon-like peptide-1 receptor agonist semaglutide attenuates neuroinflammation in this model. Neurology. 2023;100(17).","DOI":"10.1212\/WNL.0000000000203487"},{"issue":"1","key":"2166_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, et al. Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17(1):14.","journal-title":"Alzheimers Res Ther"},{"key":"2166_CR49","unstructured":"Cummings JL et al. Evoke and evoke+: Two phase 3 randomised placebo-controlled trials of semaglutide in participants with early-stage Alzheimer\u2019s disease (NCT04777396 and NCT04777409). In: 18th clinical trials on Alzheimer\u2019s disease (CTAD 2025). San Diego, CA, USA: Novo Nordisk; 2025."},{"key":"2166_CR50","unstructured":"Frederiksen KS et al. Effects of semaglutide on Alzheimer\u2019s disease-related biological processes: results from a biofluid biomarker and multiomics immunophenotyping phase 3 Study in patients with early Alzheimer\u2019s disease after 12 weeks of treatment. In: 18th clinical trials on Alzheimer\u2019s disease (CTAD 2025). San Diego , US Nova Nordisk; 2025."},{"key":"2166_CR51","doi-asserted-by":"crossref","unstructured":"Wang W et al. Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study. J Alzheimers Dis. 2025;13872877251351329.","DOI":"10.1177\/13872877251351329"},{"issue":"12","key":"2166_CR52","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, et al. Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20(12):8661\u201372.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2166_CR53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.21016","volume":"8","author":"HT Lin","year":"2025","unstructured":"Lin HT, et al. Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity. JAMA Netw Open. 2025;8(7):e2521016.","journal-title":"JAMA Netw Open"},{"issue":"Pt 3","key":"2166_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113537","volume":"143","author":"N Siddeeque","year":"2024","unstructured":"Siddeeque N, et al. Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study. Int Immunopharmacol. 2024;143(Pt 3):113537.","journal-title":"Int Immunopharmacol"},{"key":"2166_CR55","doi-asserted-by":"publisher","first-page":"1315248","DOI":"10.1155\/2022\/1315248","volume":"2022","author":"B Huang","year":"2022","unstructured":"Huang B, et al. The Innate and adaptive immune cells in Alzheimer\u2019s and Parkinson\u2019s diseases. Oxid Med Cell Longev. 2022;2022:1315248.","journal-title":"Oxid Med Cell Longev"},{"key":"2166_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314753","author":"S Yi","year":"2022","unstructured":"Yi S, et al. Pathogenesis of \u03b1-Synuclein in Parkinson\u2019s disease: from a neuron-glia crosstalk perspective. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232314753.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2166_CR57","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1093\/brain\/awaa269","volume":"143","author":"J Galiano-Landeira","year":"2020","unstructured":"Galiano-Landeira J, et al. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson\u2019s disease. Brain. 2020;143(12):3717\u201333.","journal-title":"Brain"},{"issue":"4","key":"2166_CR58","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JPD-130250","volume":"3","author":"GT Kannarkat","year":"2013","unstructured":"Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson\u2019s disease. J Parkinsons Dis. 2013;3(4):493\u2013514.","journal-title":"J Parkinsons Dis"},{"key":"2166_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13040634","author":"K Chen","year":"2023","unstructured":"Chen K, et al. Microglia and astrocytes dysfunction and key neuroinflammation-based biomarkers in Parkinson\u2019s disease. Brain Sci. 2023. https:\/\/doi.org\/10.3390\/brainsci13040634.","journal-title":"Brain Sci"},{"key":"2166_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2023.113692","volume":"174","author":"YT Zhou","year":"2023","unstructured":"Zhou YT, et al. Inactivation of microglia dampens blood-brain barrier permeability and loss of dopaminergic neurons in paraquat-lesioned mice. Food Chem Toxicol. 2023;174:113692.","journal-title":"Food Chem Toxicol"},{"key":"2166_CR61","volume":"2011","author":"D Litteljohn","year":"2010","unstructured":"Litteljohn D, et al. Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson\u2019s disease. Parkinsons Dis. 2010;2011:713517.","journal-title":"Parkinsons Dis"},{"issue":"1","key":"2166_CR62","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1038\/s41467-021-26519-x","volume":"12","author":"S Bido","year":"2021","unstructured":"Bido S, et al. Microglia-specific overexpression of \u03b1-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity. Nat Commun. 2021;12(1):6237.","journal-title":"Nat Commun"},{"key":"2166_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.639414","volume":"15","author":"C Rom\u00e1n-Vendrell","year":"2021","unstructured":"Rom\u00e1n-Vendrell C, et al. Effects of excess brain-derived human \u03b1-synuclein on synaptic vesicle trafficking. Front Neurosci. 2021;15:639414.","journal-title":"Front Neurosci"},{"issue":"47","key":"2166_CR64","doi-asserted-by":"publisher","first-page":"20051","DOI":"10.1073\/pnas.0908005106","volume":"106","author":"KC Luk","year":"2009","unstructured":"Luk KC, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009;106(47):20051\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2166_CR65","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/ncomms2534","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim C, et al. Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.","journal-title":"Nat Commun"},{"issue":"3","key":"2166_CR66","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/glia.22437","volume":"61","author":"L Fellner","year":"2013","unstructured":"Fellner L, et al. Toll-like receptor 4 is required for \u03b1-synuclein dependent activation of microglia and astroglia. Glia. 2013;61(3):349\u201360.","journal-title":"Glia"},{"issue":"47","key":"2166_CR67","doi-asserted-by":"publisher","first-page":"18754","DOI":"10.1073\/pnas.0704908104","volume":"104","author":"A Ghosh","year":"2007","unstructured":"Ghosh A, et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson\u2019s disease. Proc Natl Acad Sci U S A. 2007;104(47):18754\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2166_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103787","volume":"85","author":"T Liu","year":"2025","unstructured":"Liu T, et al. Decoding Parkinson\u2019s disease: the interplay of cell death pathways, oxidative stress, and therapeutic innovations. Redox Biol. 2025;85:103787.","journal-title":"Redox Biol"},{"issue":"1","key":"2166_CR69","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41531-023-00502-3","volume":"9","author":"R Di Maio","year":"2023","unstructured":"Di Maio R, et al. Neuroprotective actions of a fatty acid nitroalkene in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9(1):55.","journal-title":"NPJ Parkinsons Dis"},{"key":"2166_CR70","volume":"2022","author":"Y Li","year":"2022","unstructured":"Li Y, et al. Oxidative stress and 4-hydroxy-2-nonenal (4-HNE): implications in the pathogenesis and treatment of aging-related diseases. J Immunol Res. 2022;2022:2233906.","journal-title":"J Immunol Res"},{"key":"2166_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14060696","author":"ZZ Chong","year":"2025","unstructured":"Chong ZZ, Souayah N. Oxidative stress: pathological driver in chronic neurodegenerative diseases. Antioxidants. 2025. https:\/\/doi.org\/10.3390\/antiox14060696.","journal-title":"Antioxidants"},{"issue":"6","key":"2166_CR72","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/glia.23970","volume":"69","author":"AF Pike","year":"2021","unstructured":"Pike AF, et al. \u03b1-Synuclein evokes NLRP3 inflammasome-mediated IL-1\u03b2 secretion from primary human microglia. Glia. 2021;69(6):1413\u201328.","journal-title":"Glia"},{"key":"2166_CR73","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41531-017-0032-2","volume":"3","author":"S Sarkar","year":"2017","unstructured":"Sarkar S, et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson\u2019s disease. NPJ Parkinsons Dis. 2017;3:30.","journal-title":"NPJ Parkinsons Dis"},{"issue":"6","key":"2166_CR74","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41423-025-01284-9","volume":"22","author":"S Paik","year":"2025","unstructured":"Paik S, et al. Updated insights into the molecular networks for NLRP3 inflammasome activation. Cell Mol Immunol. 2025;22(6):563\u201396.","journal-title":"Cell Mol Immunol"},{"key":"2166_CR75","doi-asserted-by":"publisher","first-page":"1039780","DOI":"10.3389\/fnagi.2022.1039780","volume":"14","author":"R Zhu","year":"2022","unstructured":"Zhu R, et al. The role of microglial autophagy in Parkinson\u2019s disease. Front Aging Neurosci. 2022;14:1039780.","journal-title":"Front Aging Neurosci"},{"issue":"43","key":"2166_CR76","doi-asserted-by":"publisher","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","volume":"29","author":"B Spencer","year":"2009","unstructured":"Spencer B, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson\u2019s and Lewy body diseases. J Neurosci. 2009;29(43):13578\u201388.","journal-title":"J Neurosci"},{"issue":"6","key":"2166_CR77","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/jnc.14308","volume":"144","author":"J Zhang","year":"2018","unstructured":"Zhang J, et al. Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson\u2019s disease. J Neurochem. 2018;144(6):691\u2013709.","journal-title":"J Neurochem"},{"issue":"14","key":"2166_CR78","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1523\/JNEUROSCI.1508-21.2022","volume":"42","author":"CK Oh","year":"2022","unstructured":"Oh CK, et al. S-Nitrosylation of p62 inhibits autophagic flux to promote \u03b1-Synuclein secretion and spread in Parkinson\u2019s disease and Lewy body dementia. J Neurosci. 2022;42(14):3011\u201324.","journal-title":"J Neurosci"},{"issue":"1","key":"2166_CR79","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1038\/s41467-023-44033-0","volume":"14","author":"N Furthmann","year":"2023","unstructured":"Furthmann N, et al. NEMO reshapes the \u03b1-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62. Nat Commun. 2023;14(1):8368.","journal-title":"Nat Commun"},{"key":"2166_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-025-02291-8","author":"X Liu","year":"2025","unstructured":"Liu X, et al. LRRK2 mediates \u03b1-Synuclein-induced neuroinflammation and ferroptosis through the p62-Keap1-Nrf2 pathway in Parkinson\u2019s disease. Inflammation. 2025. https:\/\/doi.org\/10.1007\/s10753-025-02291-8.","journal-title":"Inflammation"},{"key":"2166_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120111","volume":"291","author":"AV Ulasov","year":"2022","unstructured":"Ulasov AV, et al. Nrf2\/Keap1\/ARE signaling: Towards specific regulation. Life Sci. 2022;291:120111.","journal-title":"Life Sci"},{"issue":"1","key":"2166_CR82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40478-021-01209-3","volume":"9","author":"A Delaidelli","year":"2021","unstructured":"Delaidelli A, et al. \u03b1-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response. Acta Neuropathol Commun. 2021;9(1):105.","journal-title":"Acta Neuropathol Commun"},{"key":"2166_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10071069","author":"F Villavicencio Tejo","year":"2021","unstructured":"Villavicencio Tejo F, Quintanilla RA. Contribution of the Nrf2 pathway on oxidative damage and mitochondrial failure in Parkinson and Alzheimer\u2019s disease. Antioxidants. 2021. https:\/\/doi.org\/10.3390\/antiox10071069.","journal-title":"Antioxidants"},{"issue":"5","key":"2166_CR84","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.4103\/1673-5374.355816","volume":"18","author":"CX Tang","year":"2023","unstructured":"Tang CX, et al. Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson\u2019s disease. Neural Regen Res. 2023;18(5):1107\u201317.","journal-title":"Neural Regen Res"},{"key":"2166_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020456","author":"M Duarte Azevedo","year":"2020","unstructured":"Duarte Azevedo M, Sander S, Tenenbaum L. GDNF, a neuron-derived factor upregulated in glial cells during disease. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9020456.","journal-title":"J Clin Med"},{"issue":"3","key":"2166_CR86","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.nbd.2012.04.014","volume":"47","author":"SM Rocha","year":"2012","unstructured":"Rocha SM, et al. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol Dis. 2012;47(3):407\u201315.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"2166_CR87","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang L, Li L, H\u00f6lscher C. Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease. J Parkinsons Dis. 2019;9(1):157\u201371.","journal-title":"J Parkinsons Dis"},{"key":"2166_CR88","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","volume":"71","author":"L Zhang","year":"2018","unstructured":"Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model. Neuropeptides. 2018;71:70\u201380.","journal-title":"Neuropeptides"},{"key":"2166_CR89","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1428817","volume":"2022","author":"L Zhang","year":"2022","unstructured":"Zhang L, et al. DA5-CH and semaglutide protect against neurodegeneration and reduce \u03b1-synuclein levels in the 6-OHDA Parkinson\u2019s disease rat model. Parkinsons Dis. 2022;2022:1428817.","journal-title":"Parkinsons Dis"},{"issue":"2","key":"2166_CR90","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/JPD-200002","volume":"10","author":"K McFarthing","year":"2020","unstructured":"McFarthing K, Larson D, Simuni T. Clinical trial highlights - GLP-1 agonists. J Parkinsons Dis. 2020;10(2):355\u201368.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2166_CR91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12974-022-02408-y","volume":"19","author":"E Kamma","year":"2022","unstructured":"Kamma E, et al. Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. J Neuroinflammation. 2022;19(1):45.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"2166_CR92","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00401-020-02189-9","volume":"140","author":"K He\u00df","year":"2020","unstructured":"He\u00df K, et al. Lesion stage-dependent causes for impaired remyelination in MS. Acta Neuropathol. 2020;140(3):359\u201375.","journal-title":"Acta Neuropathol"},{"key":"2166_CR93","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/2051-5960-1-84","volume":"1","author":"DW Hampton","year":"2013","unstructured":"Hampton DW, et al. Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol Commun. 2013;1:84.","journal-title":"Acta Neuropathol Commun"},{"key":"2166_CR94","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.coi.2017.08.013","volume":"49","author":"CA Dendrou","year":"2017","unstructured":"Dendrou CA, Fugger L. Immunomodulation in multiple sclerosis: promises and pitfalls. Curr Opin Immunol. 2017;49:37\u201343.","journal-title":"Curr Opin Immunol"},{"key":"2166_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032336","author":"G Kumar","year":"2023","unstructured":"Kumar G, Axtell RC. Dual role of B cells in multiple sclerosis. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24032336.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2166_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111189","volume":"40","author":"S Pandey","year":"2022","unstructured":"Pandey S, et al. Disease-associated oligodendrocyte responses across neurodegenerative diseases. Cell Rep. 2022;40(8):111189.","journal-title":"Cell Rep"},{"issue":"35","key":"2166_CR97","doi-asserted-by":"publisher","first-page":"21512","DOI":"10.1073\/pnas.2011249117","volume":"117","author":"S Kuerten","year":"2020","unstructured":"Kuerten S, et al. Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. Proc Natl Acad Sci USA. 2020;117(35):21512\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2166_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00760","volume":"11","author":"J van Langelaar","year":"2020","unstructured":"van Langelaar J, et al. B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Front Immunol. 2020;11:760.","journal-title":"Front Immunol"},{"issue":"1","key":"2166_CR99","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1038\/s41467-023-38703-2","volume":"14","author":"S Aydin","year":"2023","unstructured":"Aydin S, et al. Antigen recognition detains CD8(+) T cells at the blood-brain barrier and contributes to its breakdown. Nat Commun. 2023;14(1):3106.","journal-title":"Nat Commun"},{"key":"2166_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.824411","volume":"13","author":"M Kunkl","year":"2022","unstructured":"Kunkl M, et al. Astrocytes and inflammatory T helper cells: a dangerous liaison in multiple sclerosis. Front Immunol. 2022;13:824411.","journal-title":"Front Immunol"},{"issue":"3","key":"2166_CR101","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2353\/ajpath.2010.100087","volume":"177","author":"MK Desai","year":"2010","unstructured":"Desai MK, et al. Early oligodendrocyte\/myelin pathology in Alzheimer\u2019s disease mice constitutes a novel therapeutic target. Am J Pathol. 2010;177(3):1422\u201335.","journal-title":"Am J Pathol"},{"key":"2166_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996469","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, et al. Autoreactive lymphocytes in multiple sclerosis: pathogenesis and treatment target. Front Immunol. 2022;13:996469.","journal-title":"Front Immunol"},{"key":"2166_CR103","doi-asserted-by":"publisher","first-page":"1199313","DOI":"10.3389\/fnmol.2023.1199313","volume":"16","author":"K Maciak","year":"2023","unstructured":"Maciak K, Dziedzic A, Saluk J. Remyelination in multiple sclerosis from the miRNA perspective. Front Mol Neurosci. 2023;16:1199313.","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"2166_CR104","first-page":"1","volume":"9","author":"N Kandezi","year":"2020","unstructured":"Kandezi N, et al. Novel insight to neuroprotective potential of curcumin: a mechanistic review of possible involvement of mitochondrial biogenesis and PI3\/Akt\/ GSK3 or PI3\/Akt\/CREB\/BDNF signaling pathways. Int J Mol Cell Med. 2020;9(1):1\u201332.","journal-title":"Int J Mol Cell Med"},{"issue":"1","key":"2166_CR105","volume":"1","author":"DW Maixner","year":"2013","unstructured":"Maixner DW, Weng HR. The role of glycogen synthase kinase 3 beta in neuroinflammation and pain. J Pharm Pharmacol (Los Angel). 2013;1(1):001.","journal-title":"J Pharm Pharmacol (Los Angel)"},{"issue":"1","key":"2166_CR106","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1046\/j.1471-4159.2002.00939.x","volume":"82","author":"L Mai","year":"2002","unstructured":"Mai L, Jope RS, Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem. 2002;82(1):75\u201383.","journal-title":"J Neurochem"},{"key":"2166_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103984","volume":"65","author":"N Karimi","year":"2022","unstructured":"Karimi N, et al. Blood levels of brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis (MS): a systematic review and meta-analysis. Mult Scler Relat Disord. 2022;65:103984.","journal-title":"Mult Scler Relat Disord"},{"key":"2166_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.787258","volume":"15","author":"S Saha","year":"2021","unstructured":"Saha S, et al. A perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in Alzheimer\u2019s and Parkinson\u2019s diseases. Front Cell Neurosci. 2021;15:787258.","journal-title":"Front Cell Neurosci"},{"key":"2166_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.11.017","volume":"21","author":"F Sivandzade","year":"2019","unstructured":"Sivandzade F, et al. NRF2 and NF-\u049bB interplay in cerebrovascular and neurodegenerative disorders: molecular mechanisms and possible therapeutic approaches. Redox Biol. 2019;21:101059.","journal-title":"Redox Biol"},{"key":"2166_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417223","author":"D Tonev","year":"2023","unstructured":"Tonev D, Momchilova A. Oxidative stress and the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in multiple sclerosis: focus on certain exogenous and endogenous Nrf2 activators and therapeutic plasma exchange modulation. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242417223.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2166_CR111","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11011-019-00488-z","volume":"35","author":"A Nellessen","year":"2020","unstructured":"Nellessen A, et al. Nrf2 deficiency increases oligodendrocyte loss, demyelination, neuroinflammation and axonal damage in an MS animal model. Metab Brain Dis. 2020;35(2):353\u201362.","journal-title":"Metab Brain Dis"},{"key":"2166_CR112","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fimmu.2020.00391","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, et al. Nuclear factor \u03baB (NF-\u03baB)-mediated inflammation in multiple sclerosis. Front Immunol. 2020;11:391.","journal-title":"Front Immunol"},{"key":"2166_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/biom12040538","author":"TG Schreiner","year":"2022","unstructured":"Schreiner TG, Romanescu C, Popescu BO. The blood-brain barrier-a key player in multiple sclerosis disease mechanisms. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12040538.","journal-title":"Biomolecules"},{"key":"2166_CR114","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcdb.2020.10.013","volume":"116","author":"L Kirby","year":"2021","unstructured":"Kirby L, Castelo-Branco G. Crossing boundaries: interplay between the immune system and oligodendrocyte lineage cells. Semin Cell Dev Biol. 2021;116:45\u201352.","journal-title":"Semin Cell Dev Biol"},{"key":"2166_CR115","doi-asserted-by":"publisher","first-page":"1213448","DOI":"10.3389\/fimmu.2023.1213448","volume":"14","author":"N Gonzalez Caldito","year":"2023","unstructured":"Gonzalez Caldito N. Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders. Front Immunol. 2023;14:1213448.","journal-title":"Front Immunol"},{"issue":"1","key":"2166_CR116","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, et al. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther. 2023;8(1):359.","journal-title":"Signal Transduct Target Ther"},{"key":"2166_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.742065","volume":"15","author":"L Muzio","year":"2021","unstructured":"Muzio L, Viotti A, Martino G. Microglia in neuroinflammation and neurodegeneration: from understanding to therapy. Front Neurosci. 2021;15:742065.","journal-title":"Front Neurosci"},{"key":"2166_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/cells12111450","author":"CF Valori","year":"2023","unstructured":"Valori CF, et al. Astrocytes: dissecting their diverse roles in amyotrophic lateral sclerosis and frontotemporal dementia. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12111450.","journal-title":"Cells"},{"key":"2166_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015430","author":"F Provenzano","year":"2023","unstructured":"Provenzano F, et al. The key role of astrocytes in amyotrophic lateral sclerosis and their commitment to glutamate excitotoxicity. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242015430.","journal-title":"Int J Mol Sci"},{"key":"2166_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/biology12101307","author":"J You","year":"2023","unstructured":"You J, et al. Microglia and astrocytes in amyotrophic lateral sclerosis: disease-associated states, pathological roles, and therapeutic potential. Biology. 2023. https:\/\/doi.org\/10.3390\/biology12101307.","journal-title":"Biology"},{"key":"2166_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101391","author":"JM Al-Khayri","year":"2024","unstructured":"Al-Khayri JM, et al. Amyotrophic lateral sclerosis: insights and new prospects in disease pathophysiology, biomarkers and therapies. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17101391.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"2166_CR122","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40035-025-00475-8","volume":"14","author":"K Gaweda-Walerych","year":"2025","unstructured":"Gaweda-Walerych K, et al. Progranulin deficiency in the brain: the interplay between neuronal and non-neuronal cells. Transl Neurodegener. 2025;14(1):18.","journal-title":"Transl Neurodegener"},{"key":"2166_CR123","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fnmol.2019.00258","volume":"12","author":"TH Palpagama","year":"2019","unstructured":"Palpagama TH, et al. The role of microglia and astrocytes in Huntington\u2019s disease. Front Mol Neurosci. 2019;12:258.","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"2166_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01786-z","volume":"12","author":"JV Wetering","year":"2024","unstructured":"Wetering JV, et al. Neuroinflammation is associated with Alzheimer\u2019s disease co-pathology in dementia with Lewy bodies. Acta Neuropathol Commun. 2024;12(1):73.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2166_CR125","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2337\/db08-0799","volume":"58","author":"B Martin","year":"2009","unstructured":"Martin B, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington\u2019s disease. Diabetes. 2009;58(2):318\u201328.","journal-title":"Diabetes"},{"issue":"2","key":"2166_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032008","volume":"7","author":"Y Li","year":"2012","unstructured":"Li Y, et al. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS ONE. 2012;7(2):e32008.","journal-title":"PLoS ONE"},{"key":"2166_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101313","author":"A Harej Hrka\u0107","year":"2024","unstructured":"Harej Hrka\u0107 A, et al. The therapeutic potential of glucagon-like peptide 1 receptor agonists in traumatic brain injury. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17101313.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"2166_CR128","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4103\/bc.bc_38_24","volume":"10","author":"R Mi","year":"2024","unstructured":"Mi R, et al. Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia\/reperfusion in rats. Brain Circ. 2024;10(4):354\u201365.","journal-title":"Brain Circ"},{"key":"2166_CR129","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6813017","volume":"2022","author":"DX Liu","year":"2022","unstructured":"Liu DX, et al. Semaglutide protects against 6-OHDA toxicity by enhancing autophagy and inhibiting oxidative stress. Parkinsons Dis. 2022;2022:6813017.","journal-title":"Parkinsons Dis"},{"key":"2166_CR130","unstructured":"Johannsen P et al. Semaglutide concentration in cerebrospinal fluid from patients with early Alzheimer\u2019s disease after 12 weeks of subcutaneous treatment. In: 18th clinical trials on Alzheimer\u2019s disease (CTAD 2025). San Diego , US: Nova Nordisk; 2025."}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02166-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02166-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02166-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:03:59Z","timestamp":1767884639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-025-02166-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2166"],"URL":"https:\/\/doi.org\/10.1007\/s00011-025-02166-6","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethics approval was not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No consent is needed, as the study did not involve human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No consent is needed, as this manuscript contains no personal data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"13"}}